There are currently 917 clinical trials in Washington, District Of Columbia looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's National Medical Center, MedStar Georgetown University Hospital, MedStar Washington Hospital Center and Walter Reed Army Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Spinal Cord Injury Model Systems (SCIMS) - Education Module
NCT06003686
Recruiting
The purpose of this study is to find out if receiving education regarding increased risks of cardiometabolic disease helps subjects understand these risks and how these risks participants' health.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/13/2024
Locations: MedStar National Rehabilitation Network, Washington, District of Columbia
Conditions: Spinal Cord Injuries, Obesity, Cardiometabolic Syndrome
Register for Updates
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
NCT05696392
Recruiting
The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: The Gw Medical Faculty Associates, Washington, District of Columbia
Conditions: Atopic Dermatitis
Register for Updates
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
NCT04488081
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: COVID-19
Register for Updates
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
NCT05584202
Recruiting
The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to < 6 months.
Gender:
All
Ages:
Between 2 months and 6 months
Trial Updated:
03/12/2024
Locations: Meridian Clinical Research (Washington) - PPDS, Washington, District of Columbia
Conditions: SARS-CoV-2
Register for Updates
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
03/11/2024
Locations: Research Site, Washington, District of Columbia
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
NCT04841148
Recruiting
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: Breast Cancer
Register for Updates
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
NCT04544007
Recruiting
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy. There will also be secondary and exploratory objectives listed in the detailed description below.
Gender:
All
Ages:
22 years and below
Trial Updated:
03/08/2024
Locations: Children's National Medical Center (Site 775), Washington, District of Columbia
Conditions: NF1, Low-grade Glioma
Register for Updates
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663
Recruiting
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this study is to test whether Gemcitabine + Docetaxel is a better or worse treatment than the usual BCG therapy approach. The primary objective of this study is to determine the event free survival (EFS) of BCG-naïve high gr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia +3 locations
Conditions: Non-muscle-invasive Bladder Cancer
Register for Updates
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
NCT04551131
Recruiting
This study is a multi-site Phase Ib/II, 2-arm non-randomized clinical trial to determine the efficacy and tolerability of a response-adapted regimen combining ruxolitinib, dexamethasone, and etoposide as Frontline therapy for patients with newly diagnosed hemophagocytic lymphohistiocytosis (HLH) or as Salvage therapy for patients with relapsed/refractory HLH. Primary Objective To determine the efficacy and tolerability of a response-adapted ruxolitinib-containing regimen for patients with newl... Read More
Gender:
All
Ages:
Between 6 weeks and 22 years
Trial Updated:
03/08/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Hemophagocytic Lymphohistiocytosis
Register for Updates
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
NCT05467176
Recruiting
This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX.
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Urologic Surgeons of Washington, Washington, District of Columbia
Conditions: Prostate Cancer
Register for Updates
A Study to Assess Growth in Children With Idiopathic Short Stature
NCT06309979
Recruiting
Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.
Gender:
All
Ages:
Between 3 years and 16 years
Trial Updated:
03/07/2024
Locations: Children's National Health System, Washington, District of Columbia
Conditions: Idiopathic Short Stature
Register for Updates
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
NCT05661201
Recruiting
The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors. The main question it aims to answer is to find the recommended dose and scheduled for the combination of NEROFE and doxorubicin. Participants will receive weekly doses of NEROFE and doxorubicin.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia
Conditions: Solid Tumor, KRAS Mutation-Related Tumors
Register for Updates